Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | Vsig10l | Rat | 17beta-estradiol | multiple interactions | ISO | VSIG10L (Homo sapiens) | 6480464 | [Estradiol co-treated with TGFB1 protein] results in increased expression of VSIG10L mRNA | CTD | PMID:30165855 | Vsig10l | Rat | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of VSIG10L mRNA | CTD | PMID:21632981 | Vsig10l | Rat | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of VSIG10L mRNA | CTD | PMID:33387578 | Vsig10l | Rat | 2-hydroxypropanoic acid | decreases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of VSIG10L mRNA | CTD | PMID:30851411 | Vsig10l | Rat | amphetamine | increases expression | EXP | | 6480464 | Amphetamine results in increased expression of VSIG10L mRNA | CTD | PMID:30779732 | Vsig10l | Rat | antirheumatic drug | increases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Antirheumatic Agents results in increased expression of VSIG10L mRNA | CTD | PMID:24449571 | Vsig10l | Rat | arsane | multiple interactions | ISO | VSIG10L (Homo sapiens) | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of VSIG10L more ... | CTD | PMID:32525701 | Vsig10l | Rat | arsenic atom | multiple interactions | ISO | VSIG10L (Homo sapiens) | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of VSIG10L more ... | CTD | PMID:32525701 | Vsig10l | Rat | benzo[a]pyrene | affects methylation | ISO | VSIG10L (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of VSIG10L promoter | CTD | PMID:27901495 | Vsig10l | Rat | benzo[a]pyrene | decreases methylation | ISO | VSIG10L (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased methylation of VSIG10L 3' UTR | CTD | PMID:27901495 | Vsig10l | Rat | Benzo[k]fluoranthene | decreases expression | ISO | Vsig10l (Mus musculus) | 6480464 | benzo(k)fluoranthene results in decreased expression of VSIG10L mRNA | CTD | PMID:26377693 | Vsig10l | Rat | beta-lapachone | decreases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | beta-lapachone results in decreased expression of VSIG10L mRNA | CTD | PMID:38218311 | Vsig10l | Rat | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of VSIG10L mRNA | CTD | PMID:25181051|PMID:30816183 | Vsig10l | Rat | bisphenol F | decreases methylation | ISO | VSIG10L (Homo sapiens) | 6480464 | bisphenol F results in decreased methylation of VSIG10L gene | CTD | PMID:31601247 | Vsig10l | Rat | bisphenol F | decreases expression | ISO | Vsig10l (Mus musculus) | 6480464 | bisphenol F results in decreased expression of VSIG10L mRNA | CTD | PMID:38685157 | Vsig10l | Rat | butanal | decreases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | butyraldehyde results in decreased expression of VSIG10L mRNA | CTD | PMID:26079696 | Vsig10l | Rat | cadmium atom | multiple interactions | ISO | Vsig10l (Mus musculus) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of VSIG10L more ... | CTD | PMID:28111341 | Vsig10l | Rat | cadmium dichloride | multiple interactions | ISO | Vsig10l (Mus musculus) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of VSIG10L more ... | CTD | PMID:28111341 | Vsig10l | Rat | cisplatin | multiple interactions | ISO | VSIG10L (Homo sapiens) | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of VSIG10L mRNA | CTD | PMID:27392435 | Vsig10l | Rat | copper atom | increases expression | EXP | | 6480464 | Copper deficiency results in increased expression of VSIG10L mRNA | CTD | PMID:26033743 | Vsig10l | Rat | copper(0) | increases expression | EXP | | 6480464 | Copper deficiency results in increased expression of VSIG10L mRNA | CTD | PMID:26033743 | Vsig10l | Rat | copper(II) sulfate | decreases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Copper Sulfate results in decreased expression of VSIG10L mRNA | CTD | PMID:19549813 | Vsig10l | Rat | cyclosporin A | decreases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Cyclosporine results in decreased expression of VSIG10L mRNA | CTD | PMID:27989131 | Vsig10l | Rat | dichloroacetic acid | increases expression | ISO | Vsig10l (Mus musculus) | 6480464 | Dichloroacetic Acid results in increased expression of VSIG10L mRNA | CTD | PMID:28962523 | Vsig10l | Rat | dorsomorphin | multiple interactions | ISO | VSIG10L (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased more ... | CTD | PMID:27188386 | Vsig10l | Rat | entinostat | increases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | entinostat results in increased expression of VSIG10L mRNA | CTD | PMID:27188386 | Vsig10l | Rat | epoxiconazole | increases expression | ISO | Vsig10l (Mus musculus) | 6480464 | epoxiconazole results in increased expression of VSIG10L mRNA | CTD | PMID:35436446 | Vsig10l | Rat | folic acid | decreases expression | ISO | Vsig10l (Mus musculus) | 6480464 | Folic Acid results in decreased expression of VSIG10L mRNA | CTD | PMID:25629700 | Vsig10l | Rat | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of VSIG10L mRNA | CTD | PMID:33387578 | Vsig10l | Rat | hexadecanoic acid | decreases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Palmitic Acid results in decreased expression of VSIG10L mRNA | CTD | PMID:39506029 | Vsig10l | Rat | hydroquinone | increases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | hydroquinone results in increased expression of VSIG10L mRNA | CTD | PMID:31256213 | Vsig10l | Rat | iron atom | decreases expression | EXP | | 6480464 | Iron deficiency results in decreased expression of VSIG10L mRNA | CTD | PMID:16629162 | Vsig10l | Rat | iron(0) | decreases expression | EXP | | 6480464 | Iron deficiency results in decreased expression of VSIG10L mRNA | CTD | PMID:16629162 | Vsig10l | Rat | niclosamide | increases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Niclosamide results in increased expression of VSIG10L mRNA | CTD | PMID:36318118 | Vsig10l | Rat | okadaic acid | increases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Okadaic Acid results in increased expression of VSIG10L mRNA | CTD | PMID:38832940 | Vsig10l | Rat | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of VSIG10L mRNA | CTD | PMID:33387578 | Vsig10l | Rat | phenylmercury acetate | decreases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in decreased expression of VSIG10L mRNA | CTD | PMID:26272509 | Vsig10l | Rat | phenylmercury acetate | multiple interactions | ISO | VSIG10L (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased more ... | CTD | PMID:27188386 | Vsig10l | Rat | quercetin | increases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Quercetin results in increased expression of VSIG10L mRNA | CTD | PMID:21632981 | Vsig10l | Rat | rac-lactic acid | decreases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of VSIG10L mRNA | CTD | PMID:30851411 | Vsig10l | Rat | SB 431542 | multiple interactions | ISO | VSIG10L (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased more ... | CTD | PMID:27188386 | Vsig10l | Rat | silver atom | increases expression | ISO | Vsig10l (Mus musculus) | 6480464 | Silver results in increased expression of VSIG10L mRNA | CTD | PMID:27131904 | Vsig10l | Rat | silver(0) | increases expression | ISO | Vsig10l (Mus musculus) | 6480464 | Silver results in increased expression of VSIG10L mRNA | CTD | PMID:27131904 | Vsig10l | Rat | sodium arsenate | multiple interactions | ISO | VSIG10L (Homo sapiens) | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of VSIG10L more ... | CTD | PMID:32525701 | Vsig10l | Rat | sodium arsenite | increases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | sodium arsenite results in increased expression of VSIG10L mRNA | CTD | PMID:38568856 | Vsig10l | Rat | temozolomide | decreases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Temozolomide results in decreased expression of VSIG10L mRNA | CTD | PMID:31758290 | Vsig10l | Rat | thimerosal | decreases expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Thimerosal results in decreased expression of VSIG10L mRNA | CTD | PMID:27188386 | Vsig10l | Rat | thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of VSIG10L mRNA | CTD | PMID:34492290 | Vsig10l | Rat | titanium dioxide | decreases expression | ISO | Vsig10l (Mus musculus) | 6480464 | titanium dioxide results in decreased expression of VSIG10L mRNA | CTD | PMID:29264374 | Vsig10l | Rat | valproic acid | increases methylation | ISO | VSIG10L (Homo sapiens) | 6480464 | Valproic Acid results in increased methylation of VSIG10L gene | CTD | PMID:29154799 | Vsig10l | Rat | valproic acid | affects expression | ISO | VSIG10L (Homo sapiens) | 6480464 | Valproic Acid affects the expression of VSIG10L mRNA | CTD | PMID:25979313 | Vsig10l | Rat | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of VSIG10L mRNA | CTD | PMID:29427782 | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||






















